Correlation Engine 2.0
Clear Search sequence regions


  • adult (2)
  • amoxicillin (5)
  • antibiotics (2)
  • dyspepsia (1)
  • humans (1)
  • marrow (1)
  • patient (2)
  • peptic ulcer (1)
  • rifabutin (7)
  • Sizes of these terms reflect their relevance to your search.

    Helicobacter pylori causes dyspepsia, peptic ulcer, and gastric malignancies. Treatments for Helicobacter pylori are mostly empirical depending on regional antibiotic resistances and the patient's history and less frequently susceptibility guided. Helicobacter pylori has a low resistance to rifabutin and has been proposed as an alternative for third-line treatment and beyond but recently has also gained attention for use as first- and second-line treatment. In this review, the authors systematically searched medical databases in order to present the current eradication rates for any treatment based on the two antibiotics, rifabutin and amoxicillin with a potent acid inhibitor. They also assessed the safety and tolerance of all the relative regimens. Treatment with a rifabutin- and amoxicillin-containing regimen is a valuable option when treating difficult to eradicate Helicobacter pylori infections. Its efficacy is overall 71.4%, and it is not influenced by previous antibiotics, gender, smoking habits, and age. Its results were better when used as a first- or second-line treatment. In third-line therapy and beyond, eradication rates are lower. Adverse effects of all rifabutin regimens occurred in 23% of patients and were mostly mild with bone marrow suppression being very low and reversible.

    Citation

    Elias Xirouchakis, Sotirios D Georgopoulos. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert opinion on pharmacotherapy. 2022 Feb;23(2):201-210

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34595999

    View Full Text